**IL-35 inhibits cell pyroptosis and attenuates cell injury in TNF-α-induced bronchial epithelial cells via p38 MAPK signaling pathway**

Yanbo Wang, Yanling Yu, Wanjing Yu, Xun Bian, and Linxia Gong

Department of Pediatrics, Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated with Nanjing University of Chinese Medicine, Nanjing, Jiangsu, P.R. China

**ABSTRACT**

Asthma is a chronic inflammatory disease of the airways, and IL-35 has been found to be involved in the pathogenesis of inflammatory diseases by mediating the inhibition of effector T cells. However, the role of IL-35 on cell pyroptosis, which frequently occurs in inflammatory diseases, has not been elucidated. Therefore, the present study used a TNF-α-induced bronchial epithelial cell injury model to investigate the mechanism of IL-35 action on cell pyroptosis and asthma injury. The effects of IL-35 on cell activity, inflammatory factor levels, cell barrier damage and cell pyroptosis-related proteins were examined by CCK-8, ELISA, lucifer yellow permeability and Western blotting assay, respectively. Subsequently, following the activation of p38 MAPK signaling pathway by adding p38 agonist, the effect of IL-35 on TNF-α-induced bronchial epithelial cell injury was investigated. The results showed that IL-35 reduced TNF-α-induced cell injury, decreased inflammatory factors, improved cell permeability, and inhibited cell pyroptosis. More importantly, the effect of IL-35 on injured cells was reversed after p38 MAPK pathway was activated. In summary, IL-35 inhibited p38 MAPK pathway to suppress cell pyroptosis and thereby reduce asthma injury.

**Introduction**

Asthma is a chronic inflammatory disease of the airways [1]. In a susceptible population, this inflammation leads to recurrent episodes of wheezing, dyspnea, chest tightness and coughing. These episodes are usually connected to airflow obstruction and are reversible either spontaneous or therapeutic [1,2]. In addition, asthma causes infiltration of many inflammatory cells, excessive mucus secretion, airway remodeling and increased airway hyperresponsiveness [1–3]. However, persistent airway epithelial injury maintained the airway under high inflammatory conditions and irreversibly remodeled the airway [4]. Thus, understanding the mechanisms of airway injury is essential for the treatment of asthma.

Interleukin-35 (IL-35), a member of the IL-12 family, is a heterodimer composed of α-chain P35 and β-chain Epstein-Barr virus-induced gene 3 (EBI3) [5]. Differently from other IL-12 family members, IL-35 was highly expressed on stimulated human Treg cells, while IL-35 expression was not observed in unstimulated human Treg cells [6,7]. After stimulation with tumor necrosis factor-α (TNF-α), interferon-β (IFN-β) and interleukin-1β (IL-1β), IL-35 was upregulated in human non-T cells, including aortic smooth muscle cells, microvascular endothelial cells and epithelial cells [6,8,9]. Also, a study has demonstrated that interleukin-35 sensitizes monocytes in asthma to glucocorticoid treatment via inhibition of p38 MAPK signaling [10].

Notably, due to an increase of TNF-α mRNA and protein expression in the airways of asthmatic patients, it was raised the possibility of TNF-α participating in the dysregulation of the inflammatory response in the asthmatic airways [11]. Meanwhile, the study found that IL-35 participated in the pathogenesis of asthma some inflammatory and autoimmune diseases, including asthma, by brokering the inhibition of effector T cells [6,12]. However, studies regarding the role of IL-35 on cell pyroptosis and often occurring in inflammatory diseases are not yet clarified.

Therefore, in this study, a model of TNF-α-induced bronchial epithelial cell injury was used...
to investigate the mechanism of action of IL-35 to inhibit cell pyroptosis and thereby reduce asthma injury.

**Materials and Methods**

**Cell culture**

Human bronchial epithelial cells (BEAS-2B) were obtained from the Chinese Academy of Sciences. Cells were grown in DMEM medium containing 10% FBS and 1% penicillin-streptomycin solution. Culture bottles were placed in a standard incubator containing 5% CO₂ at 37°C.

**Cell viability**

Cell viability was measured with Cell Counting Kit-8 (CCK-8) (Solarbio Technology Co., Ltd.). Cells were seeded in 96-well plates (5 × 10³ cells/well), and cultured with 25, 50, and 100 ng/ml IL-35 for 24 h at 37°C. CCK-8 was then added to the solution and further incubated for 2 h at 37°C. The absorbance at 450 nm was recorded by using a microplate reader (Bio-Rad Laboratories, Inc.).

**Reverse transcription-qPCR (RT-qPCR)**

Total RNA was acquired by separation with a Trizol reagent (Invitrogen) according to the manufacturer's directions. Reverse transcription was conducted with a PrimeScript™ RT Reagent kit (Takara Bio, Inc.). iTag™ Universal SYBR® Green Supermix (Bio-Rad Laboratories, Inc.) was used to assay for mucin5AC (MUC5AC) and intercellular adhesion molecule-1 (ICAM-1) expression. Thermal cycling conditions: 95°C initial denaturation for 10 min; 95°C denaturation for 15 s, 60°C annealing for 1 min, 40 cycles; then 72°C extension for 10 min. Comparison of relative expression levels by 2⁻^ΔΔCq method [13]. The following primers pairs were used: MUC5AC forward 5’- GTGGTTTGACACTGACTTCCC-3’ and reverse 5’-CTCTTCTCGGTGACAGACTCTCT-3’, and ICAM-1 forward 5’- ATGCCCGACATCTGTGCTC-3’ and reverse 5’-GCGGTCCTCTATGCCCAACAA-3’, GAPDH forward 5’-ACAACTTTGTTATCGTGGAAGG-3’ and reverse 5’-GCCATCAGGCAACAGTTTC-3’.

**ELISA assay**

Interleukin-6 (IL-6), interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1) were quantified with ELISA kits. In brief, BEAS-2B cells were cultured in 96-well plates (5 × 10³ cells/well). Cells were treated for induction accordingly after 24 h. Subsequently, the cells were centrifuged at 2000 x g for 5 min at 4°C, and the supernatant was collected to detect inflammatory cytokines according to the ELISA kit instructions.

**Lucifer yellow (LY) permeability assay**

The permeability of the BEAS-2B cell barrier was assessed by measuring the LY transmittance. BEAS-2B cells were added to the top chamber of a 24-well Transwell plate with cell growth medium, and cultured at 37°C and 5% CO₂ to form BEAS-2B cell monolayers. 100 µM LY (Sigma-Aldrich, Merck KGaA) solution was added to the top chamber of the Transwell plate. After treatment with different concentrations of IL-35 at 37°C, the medium in the bottom chamber was collected and the LY concentration was measured.

**TUNEL assay**

The colorimetric TUNEL apoptosis assay kit (#C1091, Beyotime Biotechnology Inc.) was used and the assay was performed according to the manufacturer's protocol. In brief, cells were fixed with 3.7% formaldehyde at room temperature, incubated with 0.1% Triton X-100 at 4°C for 2 min, and then incubated with a methanolic solution of 0.3% H₂O₂ at room temperature for 20 min. In order to evenly distribute the rTdT reaction mixture, samples were incubated in a wet chamber at 37°C for 60 min for the end-labeling reaction. After rinsing, the reaction was stained with diaminobenzidine for 10 min, counterstained with hematoxylin, and observed under a light microscope (magnification, x200).

**Western blotting**

Proteins from BEAS-2B cells were extracted by using lysates and quantified by the BCA method. The proteins were separated by SDS-PAGE.
electrophoresis and then transferred to PVDF membranes. After sealing with 5% skim milk, the membranes were incubated overnight at 4°C with primary antibodies. The following day the membrane was incubated with secondary antibody for 1 h at room temperature. Finally, the protein bands were imaged by enhanced chemiluminescence. Protein expression levels were semi-quantified using Image-Pro Plus 6.0 (Media Cybernetics, Inc.) software.

Statistical Analysis

Statistical analyses were performed using GraphPad Prism 8.0 software (GraphPad Software, Inc.). Data are expressed as mean ± standard deviation (SD). Each experiment was repeated three times unless otherwise indicated. Statistical differences were determined using unpaired Student’s t-tests or one-way ANOVA between two groups followed by Tukey’s post hoc test between multiple groups. P < 0.05 was considered to indicate a statistically significant difference.

Results

IL-35 promotes the cell viability of TNF-α-induced BEAS-2B cells

IL-35 expression in TNF-α-induced BEAS-2B cells was detected by RT-qPCR and Western blot. The results demonstrated that the IL-35 mRNA and protein expression levels were significantly reduced in TNF-α-induced BEAS-2B cells compared to control group (Figure 1(a,b)). Cell viability results indicated that TNF-α induction significantly inhibited BEAS-2B cell viability (Figure 1(d)). The results of BEAS-2B cells treated with different concentrations of IL-35 showed that 25–100 ng/ml IL-35 had no significant effect on cell viability (Figure 1(c)). However, it is meaningful that 50–100 ng/ml IL-35 significantly increased TNF-α-induced BEAS-2B cell viability (Figure 1(d)).

IL-35 inhibits inflammatory response and mucogenesis in TNF-α-induced BEAS-2B cells

The expression of inflammatory response-related factors was detected by ELISA, and the mRNA

![Figure 1](image-url) Results of cell viability with IL-35 treatment. The (a) mRNA and (b) protein expression levels of IL-35 in TNF-α-induced BEAS-2B cells. (c) Results of cell viability with IL-35 treatment in BEAS-2B cells. (d) Results of cell viability with IL-35 treatment in TNF-α-induced BEAS-2B cells. **P < 0.01 and ****P < 0.001 vs. Control. *P < 0.05 and ####P < 0.001 vs. TNF-α. Data are expressed as mean ± SD. Each experiment was repeated three times unless otherwise indicated.
and protein expressions of MUC5AC and ICAM-1 were detected by using RT-qPCR and Western blotting. Results showed that the induction of TNF-α significantly increased the IL-6 expression compared with the control group, while IL-35 intervention significantly inhibited the IL-6 expression compared with the TNF-α-induced group, notably with 100 ng/ml IL-35 inhibiting the inflammatory factors most markedly (Figure 2(a)). Similarly, results showed that IL-8 and MCP-1 expression was significantly increased by TNF-α induction, but the IL-35 intervention had a dose-dependent decrease in IL-8 and MCP-1 expression in the TNF-α-induced group (Figure 2(b,c)). MUC5AC and ICAM-1 were examined as indicators of mucus production by RT-qPCR and Western blot (Figure 2(d,e)). It was found that both mRNA and protein expression of MUC5AC and ICAM-1 were significantly increased by the TNF-α induction. In contrast, following IL-35 intervention in TNF-α induced BEAS-2B cells, the expression of MUC5AC and ICAM-1 was significantly decreased in a dose-dependent manner compared to the nonintervention group (TNF-α group).

### IL-35 inhibits cell barrier injury and pyroptosis in TNF-α-induced BEAS-2B cells

The IL-35 effect on the TNF-α-induced BEAS-2B cell barrier was subsequently assessed by studying cellular monolayer permeability and apoptosis. The results showed that the TNF-α induction increased the cellular permeability to LY compared to control group, but decreased with the increase of IL-35 (Figure 3(a)). In addition, the apoptotic results showed that the pro-apoptotic effect of TNF-α on BEAS-2B cells was reversed with the

---

**Figure 2.** Results of inflammatory response and mucogenesis. Results of the (a) IL-6, (b) IL-8 and (c) MCP-1 expression. The (d) protein and (e) mRNA expression levels of MUC5AC and ICAM-1 in TNF-α-induced BEAS-2B cells. **P < 0.001 vs. Control. *P < 0.05, ##P < 0.01 and ###P < 0.001 vs. TNF-α. Data are expressed as mean ± SD. Each experiment was repeated three times unless otherwise indicated.
increase of IL-35 content (Figure 3(b)). The relevant proteins expression involved in cell pyroptosis was detected by Western blot. NLRP3, GSDMD-N, active caspase1 p20 and pro-caspase1 were studied as proteins mediating cell pyroptosis, and protein expression levels were significantly increased upon TNF-α induction; and when TNF-α and IL-35 coexisted, protein expression levels were significantly decreased with increasing IL-35 content compared to the TNF-α-induced group (Figure 3(c)).

**IL-35 inhibits cell inflammatory response, barrier injury and pyroptosis in TNF-α-induced BEAS-2B cells via inhibiting p38 MAPK**

To determine the downstream pathway of IL-35, p-p38/p38 protein expression was detected by Western blot in each group. Meanwhile, P79350 was used as a p38 agonist for pretreatment cells to verify that IL-35 acted through the p38 MAPK signaling pathway. TNF-α significantly increased
p-p38/p38 protein expression, while IL-35 significantly reversed the effect of TNF-α in promoting p-p38/p38 protein expression (Figure 4(a)). Since 100 ng/ml IL-35 inhibited TNF-α most markedly in the previous experiments, 100 ng/ml was considered as the examined dose of IL-35 in the subsequent experiments. Subsequently, it was found that IL-35 significantly inhibited TNF-α-induced cellular inflammatory factors, but this inhibition was reversed by P79350 (Figure 4(b–d)). Consistently, in TNF-α-induced BEAS-2B cells, cellular mucogenesis-related protein expression, could be inhibited by IL-35, but the inhibition was

Figure 4. Results of IL-35 inhibition of cell inflammatory and mucogenesis via p38 MAPK pathway. (a) p38 MAPK pathway related protein expression level. Results of the (b) IL-6, (c) IL-8 and (d) MCP-1 expression. The (e) protein and (f) mRNA expression levels of MUC5AC and ICAM-1 in TNF-α-induced BEAS-2B cells. ***P < 0.001 vs. Control. #P < 0.01 and ##P < 0.001 vs. TNF-α. ΔΔP<0.01 and ΔΔΔP<0.001 vs. TNF-α + IL-35. Data are expressed as mean ± SD. Each experiment was repeated three times unless otherwise indicated.
remarkably reversed with the activation of p38 by P79350 (Figure 4(e)). In addition, cellular monolayer permeability and apoptotic staining results illustrated that although the cell injury produced by TNF-α induction was inhibited by IL-35 intervention, however, the activation of p38 made the injury larger again (Figure 5(a, b)). Moreover, the expression of cellular pyropptosis-related proteins in TNF-induced BEAS-2B cells also showed a similar trend as above, with IL-35 inhibiting expression and P79350 reversing the inhibitory effect (Figure 5(c)).

Figure 5. Results of IL-35 inhibition of cell barrier injury and pyropptosis via p38 MAPK pathway. (a) Results of LY permeability assay. (b) Results of apoptotic cells by TUNEL assay (magnification, x200). (c) The related protein expression levels of cell pyropptosis, including NLRP3, GSDMD-N, active caspase1 p20 and pro-caspase1. ***P < 0.001 vs. Control. ###P < 0.001 vs. TNF-α. ΔΔP<0.01 and ΔΔΔP<0.001 vs. TNF-α + IL-35. Data are expressed as mean ± SD. Each experiment was repeated three times unless otherwise indicated.
**Discussion**

Asthma is an inflammatory disease of the respiratory system in which many cytokines play an important role [11]. TNF-α, a pro-inflammatory cytokine, is involved in airway inflammation and affects the therapeutic outcome [14–16]. A summary of the role of TNF-α in the pathogenesis of asthma has been reported and suggested that slowing disease progression and suppressing inflammation could be achieved by blocking the production or inhibiting the action of TNF-α [14,16,17]. In addition, in clinical study, asthma patients who received anti-TNF-α treatment showed improvement in quality of life, lung function and airway hyper-responsiveness [17]. Notably, the research on asthma inflammation using TNF-α-induced bronchial epithelial cells as a model has been reported [9,18,19]. Thus, the present study had a sufficient theoretical basis to assess the effect of IL-35 in asthma using TNF-α-induced bronchial epithelial cells as a model.

Pyroptosis is known to be a programmed inflammatory cell death activated by several inflammatory vesicles that may lead to cell swelling, plasma membrane lysis and release of intracellular pro-inflammatory contents [20]. Researchers summarized the role of pyroptosis in cardiovascular diseases and concluded that the pyroptotic signaling pathway may be a potential target for cardiovascular disease therapy [21,22]. Some progress has also been made in the field of cancer, where it has been found that pyroptosis can affect tumor proliferation, invasion and metastasis [20]. In this study, the pyroptosis signaling pathway was investigated as a target for asthma. It was shown that the protein expression level of NLRP3 was significantly increased in TNF-α-induced BEAS-2B cells compared with the control group, and similarly, the protein expression of GSDMD-N and caspase1 were also found to be significantly increased. It is worth mentioning that NLRP3, GSDMD-N and caspase1 are often studied in cell pyroptosis as proteins associated with inflammation [23]. Reports have shown that when cell pyroptosis was inhibited, the expression levels of NLRP3, GSDMD-N and caspase1 proteins were also inhibited [23–25]. Excitingly, in the present study, the protein expression levels of NLRP3, GSDMD-N and caspase1 were also suppressed due to the effect of IL-35. Thus, it is suggested that IL-35 has a remarkable inhibitory effect on TNF-α-induced BEAS-2B cell pyroptosis. In addition, it was found that TNF-α-induced cell viability was increased, inflammatory response was diminished and cell damage was reduced under the influence of IL-35.

To further investigate the mechanism of IL-35 action on cell pyroptosis in TNF-α-induced BEAS-2B cells, the p38 MAPK signaling pathway was introduced in this study. The study revealed that IL-35 could regulate IL-1β-stimulated angiogenesis in SW1353 cells and cartilage through the p38 MAPK signaling pathway [26]. And other study proved that IL-35 could increase the sensitivity of monocytes in asthma patients to glucocorticoid treatment by regulating p38 MAPK [10]. In this study, the effect of IL-35 on p38 protein expression in TNF-α-induced cells was detected by Western blot. The results again verified that IL-35 could inhibit the high expression of p38 protein, which is consistent with the findings in previous studies [10,26]. Subsequently, to further verify that IL-35 inhibited inflammatory response, cell pyroptosis and cell injury via p38 MAPK signaling pathway in TNF-α-induced BEAS-2B cells, P79350 was added to the experimental group as a p38 agonist. The results showed that the addition of P79350 markedly reversed the effects exhibited by IL-35 on TNF-α-induced cells, especially the inhibition of cell pyroptosis, thereby suggesting that IL-35 interfered with cell pyroptosis via p38 MAPK signaling pathway.

**Conclusion**

In this study, we found that IL-35 inhibited the inflammatory response, cell pyroptosis and cell injury of TNF-α-induced bronchial epithelial cells through p38 MAPK signaling pathway. In particular, IL-35 inhibited TNF-α-induced bronchial epithelial cell pyroptosis via the p38 MAPK signaling pathway, which may provide a more detailed pathway for the study of asthma inflammation. However, because of the limitations of this study, subsequent research will be validated in different cellular and animal models.
Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The author(s) reported there is no funding associated with the work featured in this article.

References

[1] National Asthma E, Prevention P. Expert panel report 3 (EPR-3): guidelines for the diagnosis and management of asthma—summary report 2007. J Allergy Clin Immunol. 2007 Nov;120(5 Suppl):S94–138.
[2] Mims JW. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol. 2015 Sep;5(Suppl 1):S2–6.
[3] Munoz X, Sanchez-Vidaurre S, Roca O, et al. Bronchial inflammation and hyperresponsiveness in well controlled asthma. Clin Exp Allergy. 2012 Sep;42(9):1321–1328.
[4] Im H, Ammit AJ. The NLRP3 inflammasome: role in airway inflammation. Clin Exp Allergy. 2014 Feb;44(2):160–172.
[5] Gao P, Su Z, Lv X, et al. Interleukin-35 in asthma and its potential as an effective therapeutic agent. Mediators Inflamm. 2017;2017:5931865.
[6] Collison LW, Chaturvedi V, Henderson AL, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010 Dec;11(12):1093–1101.
[7] Hu D. Role of anti-inflammatory cytokines IL-35 and IL-37 in asthma. Inflammation. 2017 Apr;40(2):697–707.
[8] Li X, Mai J, Virtue A, et al. IL-35 is a novel responsive anti-inflammatory cytokine—a new system of categorizing anti-inflammatory cytokines. PLoS One. 2012;7(3):e33628.
[9] Ren X, Han L, Li Y, et al. Isorhamnetin attenuates TNF-alpha-induced inflammation, proliferation, and migration in human bronchial epithelial cells via MAPK and NF-kappaB pathways. Anat Rec (Hoboken). 2021 Apr;304(4):901–913.
[10] Qian L, Xu D, Xue F, et al. Interleukin-35 sensitizes monocytes from patients with asthma to glucocorticoid therapy by regulating p38 MAPK. Exp Ther Med. 2020 May;19(5):3247–3258.
[11] Berry M, Brightling C, Pavord I, et al. TNF-alpha in asthma. Curr Opin Pharmacol. 2007 Jun;7(3):279–282.
[12] Li W, Gao R, Xin T, et al. Different expression levels of interleukin-35 in asthma phenotypes. Respir Res. 2020 Apr 16;21(1):89.
[13] Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001 Dec;25(4):402–408.
[14] Lykouras D, Sampsonas F, Kaparianos A, et al. Role and pharmacogenomics of TNF-alpha in asthma. Mini Rev Med Chem. 2008 Aug;8(9):934–942.
[15] Huang H, Nie W, Qian J, et al. Effects of TNF-alpha polymorphisms on asthma risk: a systematic review and meta-analysis. J Investig Allergol Clin Immunol. 2014;24(6):406–417.
[16] Russo C, Polosa R. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci (Lond). 2005 Aug;109(2):135–142.
[17] Brightling C, Berry M, Amrani Y. Targeting TNF-alpha: a novel therapeutic approach for asthma. J Allergy Clin Immunol. 2008 Jan;121(1):5–10; quiz 11–2.
[18] Chen M, Chen C, Gao Y, et al. Bergenin-activated SIRT1 inhibits TNF-alpha-induced proinflammatory response by blocking the NF-kappaB signaling pathway. Puls Pharmacol Ther. 2020 Jun;62:101921.
[19] Wu Y, Zou F, Lu Y, et al. SETD7 promotes TNF-alpha-induced proliferation and migration of airway smooth muscle cells in vitro through enhancing NF-kappaB/CD38 signaling. Int Immunopharmacol. 2019 Jul;72:459–466.
[20] Fang Y, Tian S, Pan Y, et al. Pyroptosis: a new frontier in cancer. Biomed Pharmacother. 2020 Jan;121:109595.
[21] Jia C, Chen H, Zhang J, et al. Role of pyroptosis in cardiovascular diseases. Int Immunopharmacol. 2019 Feb;67:311–318.
[22] Zhaolin Z, Guohua L, Shiyuan W, et al. Role of pyroptosis in cardiovascular disease. Cell Prolif. 2019 Mar;52(2):e12563.
[23] Jiang S, Zhang H, Li X, et al. Vitamin D/VDR attenuate cisplatin-induced AKI by down-regulating NLRP3/Caspase-1/GSDMD pyroptosis pathway. J Steroid Biochem Mol Biol. 2021 Feb;206:105789.
[24] Qiu Z, Lei S, Zhao B, et al. NLRP3 inflammasome activation-mediated pyroptosis aggravates myocardial ischemia/reperfusion injury in diabetic rats. Oxid Med Cell Longev. 2017;2017:9743280.
[25] Kang R, Zeng L, Zhu S, et al. Lipid peroxidation drives gasdermin D-mediated pyroptosis in lethal polymicrobial sepsis. Cell Host Microbe. 2018 Jul 11;24(1):97–108 e4.
[26] Yang J, Yao L, Li Y, et al. Interleukin-35 regulates angiogenesis through P38 mitogen-activated protein kinase signaling pathway in interleukin-1beta-stimulated SW1353 cells and cartilage bioinformatics analysis. J Interferon Cytokine Res. 2021 May;41(5):164–171.